Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study

by Ido Veisman, Oranit Barzilay, Liora Bruckmayer, Ola Haj-Natour, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin, Bella Ungar
Published 2021-09-01